Amarin Entered into an Exclusive License and Distribution Agreement with CSL Seqirus to Commercialize Vazkepa (icosapent ethyl) In Australia and New Zealand
Shots:
- Amarin will receive an up front, ~$8M in event-related milestones & ~$4M in additional product-related milestones
- CSL Seqirus will get exclusive license rights to Vazkepa from Amarin & will be responsible for market access and reimbursement efforts, distribution & commercialization of the product across Australia & New Zealand, Amarin will be responsible for supplying the finished product to CSL Seqirus in a profitable transfer price
- Icosapent ethyl is approved & sold in Canada, Lebanon, and UAE in addition to the US under the brand name Vascepa. Vascepa’s marketing authorization has been granted in Great Britain in April 2021 & the therapy is currently approved and sold in the EU in Sweden, Denmark, Finland, Austria & the UK
Ref: Amarin | Image: Amarin
Related Post:- Amarin Reports (REDUCE-IT) Trial Results of Vascepa/Vazkepa (icosapent ethyl) for Cardiovascular Diseases
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
